IBA Partners with MD Anderson to Quantify Proton Therapy's Cost-Effectiveness
Event summary
- IBA SA has entered a sponsored research agreement with MD Anderson Cancer Center to study the economic value of proton therapy.
- The research will evaluate cost-effectiveness across multiple cancer indications, led by Drs. Matthew Ning and Iakovos Toumazis.
- IBA aims to generate evidence to support reimbursement discussions and patient access in value-based care models.
- The study will assess direct and indirect costs from payer, patient, and societal perspectives.
The big picture
As healthcare systems shift toward value-based care, IBA's collaboration with MD Anderson addresses a critical gap in economic evidence for proton therapy. The research could reshape reimbursement discussions and expand access to this advanced treatment. With proton therapy's precision reducing long-term toxicity, the study's outcomes may influence broader adoption in cancer care.
What we're watching
- Evidence Generation
- Whether the research will produce definitive proof of proton therapy's cost-effectiveness compared to alternatives.
- Reimbursement Dynamics
- How the findings may influence payer policies and patient access to proton therapy.
- Industry Adoption
- The pace at which healthcare systems integrate cost-effectiveness data into treatment decision-making.
Related topics